


Neurology
11:00 AM ET
60 min
Shan Lin, Ph.D.

The focus of this webinar will be to introduce a variety of neurological disease mouse models, including models of Alzheimer's disease, Parkinson's disease, and pain. We will also discuss how to select relevant disease models to effectively evaluate novel therapeutics in vivo and how the GemPharmatech pharmacology team can help accelerate your translational research and drug discovery projects.
Topics for this webinar include:
- Overview of mouse models of neurological diseases developed by GemPharmatech
- Pharmacology service capabilities for neurological diseases
- Case study on our FAD3T Alzheimer's disease model

Shan Lin, Ph.D.
Study Director, Preclinical Service
GemPharmatech
More information about blogs


Upcoming
Selecting the right humanized mouse model is one of the most consequential decisions in immuno-oncology (IO) drug development. The wrong model can mask safety liabilities, inflate efficacy estimates, and weaken the data supporting regulatory submissions. Join GemPharmatech for a data-driven webinar on how strategic humanized mouse model selection strengthens preclinical decision-making, sharpens translational relevance, and supports IND-enabling studies.
2026-07-30 00:00:00
11:00 AM ET
Xinjie Lian


On-Demand
Hypertrophic cardiomyopathy (HCM) is a prevalent and genetically heterogeneous cardiovascular disorder, with approximately 55% of familial cases linked to mutations in sarcomeric genes. To enable mechanistic and therapeutic studies, GemPharmatech has successfully developed two HCM mouse models: the Mybpc3 knockout (KO) and the Myh6 R404Q (point mutation) strains.
2026-06-25 00:00:00
11:00 AM ET
Yue Shen, Ph.D.


On-Demand
Antibody-drug conjugates (ADCs), particularly the HER2-targeting Enhertu (DS-8201), have revolutionized targeted cancer therapy. Despite their clinical success, drug resistance remains a major hurdle limiting long-term therapeutic benefits. To address this challenge, GemPharmatech has developed multiple ADC resistance models, including a HER2-positive JIMT-1 breast cancer xenograft (CDX) model with acquired resistance to Enhertu, and a primary Enhertu-resistant HER2-positive lung cancer model from our patient-derived xenograft (PDX) library. Join us to explore how these Enhertu-resistant models serve as translational tools to elucidate resistance mechanisms and evaluate novel therapeutic strategies.
2026-04-14 00:00:00
11:00 AM ET
Shiying Guo, Ph.D.

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
